3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
354
Lymphoma
306
Lymphoma, Follicular
268
Lymphoma, Non-Hodgkin
170
Leukemia
138
Hodgkin Disease
135
Multiple Myeloma
130
Leukemia, Lymphocytic, Chronic, B-Cell
110
Lymphoma, Large B-Cell, Diffuse
108
Leukemia, Myeloid, Acute
98
Neoplasms
83
Lymphoma, Mantle-Cell
70
Burkitt Lymphoma
70
Myelodysplastic Syndromes
64
Breast Neoplasms
62
Lymphoma, T-Cell, Cutaneous
60
Lymphoma, B-Cell, Marginal Zone
59
Myeloproliferative Disorders
50
Mycosis Fungoides
50
Motor Activity
49
Lymphoma, Large-Cell, Immunoblastic
47
Sezary Syndrome
44
Neoplasms, Plasma Cell
42
Hematologic Neoplasms
41
Dementia
41
Primary Myelofibrosis
39
Leukemia, Myeloid, Chronic-Phase
38
Leukemia, Myeloid, Accelerated Phase
38
Congenital Abnormalities
38
Recurrence
37
Interventions
fludarabine phosphate
1
fludarabine
1
Mesna
1
Cyclophosphamide
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase NA
×
Thalassemia
×
Lymphoid
×
Clear all
NCT01758042
2026-03-06
BMT
Massachusetts General Hospital
Phase NA
Completed
10 enrolled
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts